倍他乐克、通心络联合治疗冠心病心绞痛的临床疗效观察  

Observation of clinical effects by betaloc and Tongxinluo in the treatment of coronary heart disease stenocardia

作　　者：胡京津 张代刚 

机构地区：[1]湖北省长阳土家族自治县鸭子口乡卫生院,443507 [2]湖北省长阳土家族自治县人民医院

出　　处：《中国实用医药》2015年第34期14-16,共3页China Practical Medicine

摘　　要：目的探讨倍他乐克、通心络联合治疗冠心病心绞痛的临床疗效。方法 128例冠心病心绞痛患者,根据治疗方法不同将患者分为对照组和观察组,各64例。对照组患者给予镇静、吸氧、口服硝酸异山梨酯片、阿司匹林肠溶片、辛伐他汀片等常规治疗,观察组在对照组治疗基础上采用倍他乐克、通心络联合治疗;治疗3个月后,评价疗效差异。结果观察组患者心绞痛改善总有效率为92.19%,高于对照组的68.75%;心电图改善总有效率为87.50%,高于对照组的75.00%;差异均具有统计学意义(P<0.05)。结论在常规治疗基础上,采用倍他乐克、通心络联合治疗冠心病心绞痛患者,可以取得较为满意的临床效果,值得临床推广应用。Objective To investigate clinical effects by betaloc and Tongxinluo in the treatment of coronary heart disease stenocardia. Methods A total of 128 patients with coronary heart disease stenocardia were randomly divided into control group and observation group, with 64 cases in each group. The control group received conventional treatment by sedation, oxygen inhalation, oral administration of isosorbide dinitrate tablets, aspirin enteric-coated tablets, and simvastatin tablets. The observation group received additional betaloc and Tongxinluo for treatment. After 3 months of treatment, their differences of curative effects were evaluated. Results The observation group had higher total effective rate of stenocardia improvement as 92.19% than 68.75% of the control group, and its total effective rate of electrocardiogram improvement was also higher as 87.50% than 75.00% of the control group. Their differences all had statistical significance（P〈0.05）. Conclusion Additional betaloc and Tongxinluo to conventional treatment can provide satisfactory clinical effect in treating coronary heart disease stenocardia. This method is worthy of clinical promotion and application.

关 键 词：倍他乐克 通心络 冠心病心绞痛 

分 类 号：R541.4[医药卫生—心血管疾病]